Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Cantargia

DB:7V3
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7V3
DB
SEK1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Cantargia has significant price volatility in the past 3 months.
7V3 Share Price and Events
7 Day Returns
3.8%
DB:7V3
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-19.5%
DB:7V3
-13.5%
DE Biotechs
-20.9%
DE Market
7V3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cantargia (7V3) 3.8% -25.4% -21.8% -19.5% - -
DE Biotechs -0.7% -7.8% -21.1% -13.5% 12.9% -11.9%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 7V3 underperformed the Biotechs industry which returned -13.5% over the past year.
  • 7V3 outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
7V3
Industry
5yr Volatility vs Market

7V3 Value

 Is Cantargia undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cantargia to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cantargia.

DB:7V3 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:7V3
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 22%) (0%))
1.126
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.126 * 5.44%)
5.73%

Discounted Cash Flow Calculation for DB:7V3 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cantargia is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:7V3 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 5.73%)
2020 575.00 Analyst x1 543.81
2021 21.50 Analyst x2 19.23
2022 251.00 Analyst x1 212.33
2023 289.88 Est @ 15.49% 231.92
2024 320.97 Est @ 10.73% 242.87
2025 344.69 Est @ 7.39% 246.67
2026 362.12 Est @ 5.06% 245.09
2027 374.51 Est @ 3.42% 239.73
2028 383.04 Est @ 2.28% 231.89
2029 388.70 Est @ 1.48% 222.56
Present value of next 10 years cash flows SEK2,436.00
DB:7V3 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK388.70 × (1 + -0.39%) ÷ (5.73% – -0.39%)
SEK6,321.70
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK6,321.70 ÷ (1 + 5.73%)10
SEK3,619.57
DB:7V3 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK2,436.00 + SEK3,619.57
SEK6,055.57
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK6,055.57 / 91.01
SEK66.54
DB:7V3 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:7V3 represents 0.08839x of OM:CANTA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.08839x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 66.54 x 0.08839
€5.88
Value per share (EUR) From above. €5.88
Current discount Discount to share price of €1.37
= -1 x (€1.37 - €5.88) / €5.88
76.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cantargia is available for.
Intrinsic value
>50%
Share price is €1.37 vs Future cash flow value of €5.88
Current Discount Checks
For Cantargia to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cantargia's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cantargia's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cantargia's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cantargia's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7V3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-1.56
OM:CANTA Share Price ** OM (2020-04-03) in SEK SEK15.5
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cantargia.

DB:7V3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:CANTA Share Price ÷ EPS (both in SEK)

= 15.5 ÷ -1.56

-9.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cantargia is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cantargia is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cantargia's expected growth come at a high price?
Raw Data
DB:7V3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
37.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cantargia, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cantargia's assets?
Raw Data
DB:7V3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK1.95
OM:CANTA Share Price * OM (2020-04-03) in SEK SEK15.5
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:7V3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:CANTA Share Price ÷ Book Value per Share (both in SEK)

= 15.5 ÷ 1.95

7.93x

* Primary Listing of Cantargia.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cantargia is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cantargia's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cantargia has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7V3 Future Performance

 How is Cantargia expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cantargia expected to grow at an attractive rate?
  • Cantargia's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Cantargia's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Cantargia's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:7V3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7V3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 37.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7V3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7V3 Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 152 251 252 2
2021-12-31 143 -141 23 2
2020-12-31 195 575 581 4
2020-04-06
DB:7V3 Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 -111 -111
2019-09-30 -97 -102
2019-06-30 -92 -98
2019-03-31 -88 -101
2018-12-31 -105 -91
2018-09-30 -72 -78
2018-06-30 -65 -68
2018-03-31 -54 -56
2017-12-31 -41 -60
2017-09-30 -69 -65
2017-06-30 -64 -66
2017-03-31 -54 -58

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cantargia's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Cantargia is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7V3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Cantargia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7V3 Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.93 2.77 -0.90 2.00
2021-12-31 0.52 2.60 -1.57 2.00
2020-12-31 6.39 6.39 6.39 1.00
2020-04-06
DB:7V3 Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -1.56
2019-09-30 -1.47
2019-06-30 -1.44
2019-03-31 -1.53
2018-12-31 -1.38
2018-09-30 -1.32
2018-06-30 -1.35
2018-03-31 -1.33
2017-12-31 -1.86
2017-09-30 -2.37
2017-06-30 -2.76
2017-03-31 -2.73

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Cantargia is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Cantargia's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cantargia has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7V3 Past Performance

  How has Cantargia performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cantargia's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cantargia does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cantargia's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cantargia's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cantargia's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cantargia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7V3 Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -110.81 13.10 97.48
2019-09-30 -102.39 12.45 89.91
2019-06-30 -97.85 14.36 83.39
2019-03-31 -100.98 16.39 84.70
2018-12-31 -91.16 15.82 76.95
2018-09-30 -77.97 9.62 104.13
2018-06-30 -67.82 8.81 87.42
2018-03-31 -55.55 6.56 65.32
2017-12-31 -60.25 7.38 52.42
2017-09-30 -64.57 14.06
2017-06-30 -65.75 13.28
2017-03-31 -57.80 11.95
2016-12-31 -47.49 11.91
2016-09-30 -33.51 11.69
2016-06-30 -24.15 10.77
2016-03-31 -21.66 10.52
2015-12-31 -17.19 9.76
2015-09-30 -14.73 8.43
2015-06-30 -13.72 7.49
2015-03-31 -10.13 5.96
2014-12-31 -8.37 4.62
2013-12-31 -7.95 2.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cantargia has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cantargia has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cantargia improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cantargia's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cantargia has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7V3 Health

 How is Cantargia's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cantargia's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cantargia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cantargia has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cantargia's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cantargia has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cantargia Company Filings, last reported 3 months ago.

DB:7V3 Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 142.27 0.00 149.89
2019-09-30 178.55 0.00 194.55
2019-06-30 204.55 0.00 219.19
2019-03-31 229.81 0.00 251.17
2018-12-31 155.05 0.00 166.85
2018-09-30 182.90 0.00 190.69
2018-06-30 204.36 0.00 212.79
2018-03-31 232.42 0.00 240.58
2017-12-31 246.12 0.00 269.78
2017-09-30 60.54 0.00 52.39
2017-06-30 71.52 0.00 66.48
2017-03-31 86.93 0.00 83.74
2016-12-31 30.04 0.00 34.84
2016-09-30 29.88 0.00 28.94
2016-06-30 42.12 0.00 39.68
2016-03-31 19.96 0.00 17.50
2015-12-31 28.06 0.00 24.51
2015-09-30 32.46 0.00 28.50
2015-06-30 35.59 0.00 33.78
2015-03-31 41.05 0.00 38.99
2014-12-31 4.10 0.00 16.66
2013-12-31 3.13 0.00 1.50
  • Cantargia has no debt.
  • Cantargia has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cantargia has sufficient cash runway for 1.3 years based on current free cash flow.
  • Unable to confirm if Cantargia has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Cantargia's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cantargia has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7V3 Dividends

 What is Cantargia's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cantargia dividends.
If you bought €2,000 of Cantargia shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cantargia's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cantargia's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7V3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7V3 Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cantargia has not reported any payouts.
  • Unable to verify if Cantargia's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cantargia's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cantargia has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cantargia's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cantargia afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cantargia has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7V3 Management

 What is the CEO of Cantargia's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Göran Forsberg
COMPENSATION SEK3,128,000
AGE 56
TENURE AS CEO 5.8 years
CEO Bio

Mr. Göran Forsberg has been the Chief Executive Officer at Cantargia AB since June 2014. Mr. Forsberg served as the Chief Business Officer of Active Biotech AB. He has more than 25 years' experience in both pharmaceutical and biotech companies. He has been with Active Biotech AB since 1998 in various positions, the last years as Chief Business Officer and member of the management team. He has significant experience in development of drug candidates within oncology. Mr. Forsberg served as the Vice President of Investor Relations and Business Development at Active Biotech AB. Mr. Forsberg has been with Active Biotech since 1998. He has worked in the pharmaceuticals industry for 20 years and held various positions at KabiGen, Pharmacia and the University of Adelaide in Australia. Mr. Forsberg has a PhD in biochemistry.

CEO Compensation
  • Göran's compensation has increased whilst company is loss making.
  • Göran's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cantargia management team in years:

4.4
Average Tenure
56
Average Age
  • The tenure for the Cantargia management team is about average.
Management Team

Göran Forsberg

TITLE
Chief Executive Officer
COMPENSATION
SEK3M
AGE
56
TENURE
5.8 yrs

Marcus Järås

TITLE
Founder & Scientific Advisor

Kjell Sjöström

TITLE

Bengt Jöndell

TITLE
Chief Financial Officer
AGE
59
TENURE
2.9 yrs

Liselotte Larsson

TITLE
Vice President of Operations
AGE
56
TENURE
6.3 yrs

Ignacio Garcia-Ribas

TITLE
Chief Medical Officer
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Cantargia board of directors in years:

4.3
Average Tenure
53.5
Average Age
  • The tenure for the Cantargia board of directors is about average.
Board of Directors

Gunnar Magnus Severus Persson

TITLE
Chairman of the Board
COMPENSATION
SEK585K
AGE
59
TENURE
4.3 yrs

Claus Andersson

TITLE
Independent Director
COMPENSATION
SEK240K
AGE
51
TENURE
7.3 yrs

Anders Martin-Löf

TITLE
Independent Director
COMPENSATION
SEK329K
AGE
48
TENURE
1.9 yrs

Thoas Fioretos

TITLE
Founder & Director
COMPENSATION
SEK256K
AGE
57
TENURE
10.3 yrs

Karin Leandersson

TITLE
Independent Director
COMPENSATION
SEK276K
AGE
47
TENURE
4.3 yrs

Patricia Delaite

TITLE
Independent Director
COMPENSATION
SEK343K
AGE
56
TENURE
2.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Cantargia individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Jan 20 Buy Göran Forsberg Individual 07. Jan 20 07. Jan 20 6,000 €1.84 €11,026
08. Jan 20 Buy Bengt Jöndell Individual 07. Jan 20 07. Jan 20 5,000 €1.78 €8,884
05. Dec 19 Buy Göran Forsberg Individual 05. Dec 19 05. Dec 19 4,000 €1.75 €7,008
02. Dec 19 Buy Bengt Jöndell Individual 02. Dec 19 02. Dec 19 15,000 €1.60 €23,979
02. Dec 19 Buy Anders Martin-Löf Individual 02. Dec 19 02. Dec 19 12,000 €1.62 €19,421
13. Jun 19 Sell Thoas Fioretos Individual 11. Jun 19 11. Jun 19 -250,000 €1.59 €-398,637
X
Management checks
We assess Cantargia's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cantargia has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7V3 News

Simply Wall St News

7V3 Company Info

Description

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.

Details
Name: Cantargia AB (publ)
7V3
Exchange: DB
Founded: 2010
SEK128,451,068
91,005,489
Website: http://www.cantargia.com
Address: Cantargia AB (publ)
Scheelevägen 2,
Medicon Village,
Lund,
Skåne County, 223 81,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM CANTA Share Capital OMX Nordic Exchange Stockholm SE SEK 17. Mar 2015
DB 7V3 Share Capital Deutsche Boerse AG DE EUR 17. Mar 2015
BATS-CHIXE CANTAS Share Capital BATS 'Chi-X Europe' GB SEK 17. Mar 2015
Number of employees
Current staff
Staff numbers
11
Cantargia employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 05:18
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/10
Last earnings filing: 2020/03/20
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.